Alpha Cognition Total Long-Term Assets 2020-2024 | ACOG
Alpha Cognition total long-term assets from 2020 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Alpha Cognition Annual Total Long-Term Assets (Millions of US $) |
2023 |
$1 |
2022 |
$1 |
2021 |
$1 |
2020 |
$1 |
2019 |
$1 |
Alpha Cognition Quarterly Total Long-Term Assets (Millions of US $) |
2024-06-30 |
$1 |
2024-03-31 |
$1 |
2023-12-31 |
$1 |
2023-09-30 |
$1 |
2023-06-30 |
$1 |
2023-03-31 |
$1 |
2022-12-31 |
$1 |
2022-09-30 |
$1 |
2022-06-30 |
$1 |
2022-03-31 |
$1 |
2021-12-31 |
$1 |
2021-09-30 |
$1 |
2021-06-30 |
$1 |
2021-03-31 |
$1 |
2020-12-31 |
$1 |
2020-09-30 |
|
2020-06-30 |
|
2020-03-31 |
|
2019-12-31 |
$1 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|